MEI Pharma Company Insiders
| MEIP Stock | USD 2.78 0.03 1.07% |
MEI Pharma's insiders are aggressively buying. The analysis of the overall insider sentiment regarding MEI Pharma suggests that virtually all insiders are extremely bullish. MEI Pharma employs about 28 people. The company is managed by 15 executives with a total tenure of roughly 27 years, averaging almost 1.0 years of service per executive, having 1.87 employees per reported executive.
| Daniel Gold CEO CEO and President and Director |
MEI Pharma's Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
| 2023-09-22 | Anson Funds Management Lp | Acquired 48060 @ 6.85 | View | ||
| 2023-09-20 | Anson Funds Management Lp | Acquired 120000 @ 6.01 | View | ||
| 2023-02-28 | Charles V Baltic III | Acquired 4075 @ 4.6 | View |
Monitoring MEI Pharma's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
MEI |
MEI Pharma's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with MEI Pharma's future performance. Based on our forecasts, it is anticipated that MEI will maintain a workforce of slightly above 200000 employees by December 2024.MEI Pharma Management Team Effectiveness
The company has return on total asset (ROA) of 0.2004 % which means that it generated a profit of $0.2004 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.6168 %, meaning that it created $0.6168 on every $100 dollars invested by stockholders. MEI Pharma's management efficiency ratios could be used to measure how well MEI Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/25/2024, Return On Tangible Assets is likely to grow to 0.45. Also, Return On Capital Employed is likely to grow to 0.46. At this time, MEI Pharma's Liabilities And Stockholders Equity is relatively stable compared to the past year. As of 11/25/2024, Non Current Liabilities Other is likely to grow to about 26.8 M, while Total Current Liabilities is likely to drop slightly above 8.3 M.As of 11/25/2024, Common Stock Shares Outstanding is likely to grow to about 7 M, while Net Loss is likely to drop (30.1 M).
MEI Pharma Workforce Comparison
MEI Pharma is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 1,505. MEI Pharma claims roughly 28.0 in number of employees contributing just under 2% to equities under Health Care industry.
The company has Profit Margin (PM) of 0.27 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.4 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.4. MEI Pharma Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific MEI Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on MEI Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, MEI Pharma insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2023-12-01 | 1.0 | 3 | 3 | 80,000 | 800.00 |
| 2023-09-01 | 7.0 | 14 | 2 | 436,100 | 15,000 |
| 2023-06-01 | 0.5 | 1 | 2 | 166,571 | 53,302 |
| 2022-09-01 | 12.0 | 12 | 1 | 4,068,588 | 8,196 |
| 2021-12-01 | 1.0 | 1 | 1 | 58,334 | 0.00 |
| 2021-09-01 | 6.0 | 12 | 2 | 2,375,000 | 66,145 |
| 2021-06-01 | 0.2222 | 2 | 9 | 80,000 | 655,000 |
| 2020-09-01 | 15.0 | 15 | 1 | 2,207,000 | 12,000 |
| 2020-06-01 | 1.0 | 1 | 1 | 30,000 | 0.00 |
| 2019-09-01 | 7.0 | 14 | 2 | 1,865,000 | 20,000 |
| 2018-09-01 | 2.2 | 11 | 5 | 1,030,000 | 150,004 |
| 2018-03-01 | 0.5 | 1 | 2 | 33,333 | 128,920 |
| 2017-12-01 | 1.0 | 1 | 1 | 11,000 | 11,000 |
| 2017-06-01 | 1.0 | 1 | 1 | 150,000 | 0.00 |
| 2015-03-01 | 5.0 | 5 | 1 | 931,020 | 1,601,390 |
| 2014-12-01 | 1.5 | 3 | 2 | 15,667 | 79,085 |
| 2013-06-01 | 0.1 | 1 | 10 | 4,063 | 733,503 |
| 2013-03-01 | 8.0 | 16 | 2 | 594,612 | 497,225 |
| 2012-12-01 | 2.0 | 10 | 5 | 15,589,589 | 20,238,246 |
| 2012-06-01 | 1.4 | 7 | 5 | 6,746,990 | 8,994,968 |
| 2011-06-01 | 2.0 | 2 | 1 | 178,620 | 0.00 |
| 2010-06-01 | 0.5 | 1 | 2 | 110,195 | 183,658 |
MEI Pharma Notable Stakeholders
A MEI Pharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as MEI Pharma often face trade-offs trying to please all of them. MEI Pharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting MEI Pharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Daniel Gold | CEO and President and Director | Profile | |
| Justin File | CFO Secretary | Profile | |
| BA Esq | COO Counsel | Profile | |
| Anne Frese | Chief Officer | Profile | |
| Eugene Park | VP Marketing | Profile | |
| Virginia Sankey | VP Fin | Profile | |
| JD Esq | Chief Officer | Profile | |
| Eric Deng | VP Operations | Profile | |
| Richard Ghalie | Chief Officer | Profile | |
| MBA MD | Chief Officer | Profile | |
| LLM JD | Senior Affairs | Profile | |
| Robert Mass | Chief Medical Officer | Profile | |
| BA CPA | CFO Sec | Profile | |
| Nicole Iida | Vice Affairs | Profile | |
| Yomara GomezNaiden | Senior Quality | Profile |
About MEI Pharma Management Performance
The success or failure of an entity such as MEI Pharma often depends on how effective the management is. MEI Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of MEI management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the MEI management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.43 | 0.45 | |
| Return On Capital Employed | 0.44 | 0.46 | |
| Return On Assets | 0.43 | 0.45 | |
| Return On Equity | 0.54 | 0.57 |
MEI Pharma Workforce Analysis
Traditionally, organizations such as MEI Pharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare MEI Pharma within its industry.MEI Pharma Manpower Efficiency
Return on MEI Pharma Manpower
| Revenue Per Employee | 2.3M | |
| Revenue Per Executive | 4.4M | |
| Net Income Per Employee | 634.9K | |
| Net Income Per Executive | 1.2M | |
| Working Capital Per Employee | 1.2M | |
| Working Capital Per Executive | 2.2M |
Additional Tools for MEI Stock Analysis
When running MEI Pharma's price analysis, check to measure MEI Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MEI Pharma is operating at the current time. Most of MEI Pharma's value examination focuses on studying past and present price action to predict the probability of MEI Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MEI Pharma's price. Additionally, you may evaluate how the addition of MEI Pharma to your portfolios can decrease your overall portfolio volatility.